Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy

Immutep LimitedJune 21, 2019

SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2014368420) entitled “Combined Preparations for the Treatment of Cancer” by the Australian Patent Office.

This Australian patent follows the recent grant of the corresponding European patent (announced 23 May 2019) and protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.

The new patent again highlights the broad potential of efti as an immunostimulant and provides patent protection in Australia for a range of novel and highly relevant chemo-immunotherapies featuring efti that may be pursued in the future.

The patent expiry date is 19 December 2034.

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2 8234 0105; mgregorowski@citadelmagnus.com

U.S. Investors:Jay Campbell, Chief Business Officer, Immutep Limited+1 (917) 860-9404; jay.campbell@immutep.com

Garth Russell, LifeSci Advisors +1 (646) 876-3613; garth@lifesciadvisors.com

All contents © copyright 2019 The Associated Press. All rights reserved.